In October, Dr. Deborah Fowell will join the college community as the next Chair of the Department of Microbiology and Immunology at the Cornell University College of Veterinary Medicine. In addition to serving as chair of the Department of Microbiology and Immunology, Dr. Fowell will join the Executive Committee of the Cornell Center for Immunology.
The current COVID-19 pandemic crisis relating to the SARS-CoV-2 virus requires research institutions such as Cornell to play a leading role in finding effective solutions to understanding the fundamental biology of this virus, combating the disease and reducing the burden on our medical (and other) establishments. To this end, the Office of the Vice Provost for Research, the Center for Vertebrate Genomics, the Center for Immunology, and the Office of Academic Integration have joined forces to provide seed funding to invest in innovative research ideas that address this critical global need. The intent of this program is to generate preliminary data for future applications for extramural support.
A free weekly research webinar series organized by a Cornell faculty member has more than 1,000 viewers – with more expected – and is quenching a thirst for science and interaction felt by researchers around the world. From early April through mid-July, the Cornell-sponsored webinar series, “Meiosis in Quarantine,” will take place every Thursday at 10 a.m. EDT on topics related to meiosis, the division of sex cells that eventually differentiate into every cell type in sexually-reproducing organisms.
An iron-regulating molecule called hepcidin is produced by the immune system and restricts the growth of gut bacteria after an intestinal injury, helping to heal the lining of the intestine, according to a study by Weill Cornell Medicine, NewYork-Presbyterian and Institut Cochin investigators. The study, published April 10 in Science, was conducted in mice and human samples and could have important implications for treating gastrointestinal diseases that damage the lining of the intestines.
New research from a team of Cornell collaborators points to a possible target for antiviral treatment for COVID-19. Their review paper, “Coronavirus Membrane Fusion Mechanism Offers a Potential Target for Antiviral Development,” published April 6 in Antiviral Research. The multidisciplinary group was led by Susan Daniel, associate professor of chemical and biomolecular engineering, and Gary Whittaker, professor of virology at the College of Veterinary Medicine.
A biomanufacturing company spun out of Cornell research is seeking to rapidly translate an antibody therapy against COVID-19 by using cell-free biotechnology based on glycoengineered bacteria. And it could scale up the production 10 times faster than conventional methods. The company, SwiftScale Biologics, was co-founded by Center member Matt DeLisa.
Brianne Barker joins Immune, co-hosted by Cynthia Leifer, to discuss the immune response to infection with SARS-CoV-2, including immune response, pathogenesis, immunopathology and more. Hosts: Vincent Racaniello, Stephanie Langel, and Cynthia Leifer Guest: Brianne Barker
As hospitals across the country try to manage a surge in coronavirus patients while also facing a global shortage in the protective gear needed to treat them, the Cornell community has banded together to donate crucial medical supplies to local health care providers.
The Cornell Center for Immunology is thrilled to share the individuals and projects that have been selected to receive Core Facilities Seed Funds.
Everyone is working together, pitching in to find solutions while suspending research and closing down laboratories. Find out what is going on and how researchers plan to be productive remotely.
